Mineralys Therapeutics, Inc. MLYS Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s cash ratio?
- Mineralys Therapeutics, Inc. (MLYS) reported cash ratio of 0.1× in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s cash ratio changed year-over-year?
- Mineralys Therapeutics, Inc.'s cash ratio decreased by 22.4% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s cash ratio?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s cash ratio has grown at a -42.4% compound annual growth rate (CAGR), from 0.4× to 0.1×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.